US equities |
SPCX $166.74 ▲+4.89% NVDA $236.86 ▲+1.24% MU $1,063.78 ▼-1.03% TSLA $377.58 ▲+1.89% MSFT $526.36 ▲+1.71% SNDK $1,713.60 ▼-0.37% INTC $117.16 ▼-1.82% META $745.20 ▲+2.35%
FinancialContent

Coya Therapeutics, Inc. - Common Stock (NQ:COYA)

4.860 +0.050 (+1.04%)
Delayed Quote Updated: 11:50 AM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Coya Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Coya Therapeutics (Coya) Announces Completion of Enrollment in a Well-Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer’s Disease (AD)
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Presents New Experimental Data Supporting the Mechanism of Action of COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) at the 22nd Annual Northeast ALS (NEALS) Consortium Meeting
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Announces the Presentation of Human Ex-Vivo Mechanistic Data Further Supporting the Development of COYA 302 for Amyotrophic Lateral Sclerosis (ALS) at the 22nd Annual Northeast ALS (NEALS) Consortium Meeting
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Analyst Expectations for Coya Therapeutics's Future ↗
 
Via Benzinga
News headline image
The Latest Analyst Ratings for Coya Therapeutics ↗
 
Via Benzinga
News headline image
Coya Therapeutics to Present at the LD Micro Investor Conference
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Licenses Exclusive Worldwide rights to Exosome Engineering Technology (EET) from Carnegie Mellon University (CMU)
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
How The Same Treatments May Work For Multiple Neurodegenerative Diseases ↗
Extensive research on NDDs has uncovered a different treatment pathway that's enabling some biotechnology firms to target more than one NDD with the same drug candidate. 
Via Talk Markets
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Coya Therapeutics Successfully Engineers Regulatory T Cell (Treg) Derived Exosomes with CTLA-4 Protein to Selectively Target Immune Cells with Potential to Deliver Targeted Therapies Across Multiple Diseases
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Announces Publication of Potential Novel Blood Biomarker Data in Amyotrophic Lateral Sclerosis (ALS) Patients That Accurately Reflect Therapeutic Responses When Treated with Regulatory T Cell (Treg) Enhancing Therapies
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics To Present Novel Proof of Concept Exosome Modification Technology at the 5th Exosome Based Therapeutic Development Summit in Boston, MA on September 7, 2023
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Former CEO and Chairman of the Board of Bayer Pharma AG, Dieter Weinand, Joins Coya’s Board of Directors
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics, Inc. Provides Business Update and Reports Q2 2023 Unaudited Financial Results
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics to Present at the BTIG Virtual Biotechnology Conference 2023
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics (“Coya”) Announces the Appointment of Dr. Merit Cudkowicz, M.D., M.Sc., as Clinical Advisor to Support the Development of COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics' Alzheimer's Candidate Shows Lower Biomarker Levels Associated With Neuroinflammation ↗
Coya Therapeutics Inc (NASDAQ: COYA) reported results from an open-label proof-of-concept clinical study for low-dose interleukin 2 (ld IL-2) in patients  
Via Benzinga
News headline image
Coya Therapeutics Reports Additional Proof-of-Concept Clinical Biomarker Data in Patients with Alzheimer’s Disease
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
The Immunotherapy Market Is Expected To Surpass $351.56 Billion By 2030 – Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) Is Contributing to This Growth ↗
Immunotherapy, in general, is an exciting and growing sector in the pharmaceutical industry. It involves manipulating the human body's immune system to treat various diseases. While historically this... 
Via Benzinga
News headline image
Coya Therapeutics (“Coya”) Appoints Industry and Drug Development Veteran, Dr. Fred Grossman, to President and Chief Medical Officer succeeding Dr. Adrian Hepner
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics to Present Proof-of-Concept Clinical Data for Low-Dose Interleukin-2 (ld IL-2) for the Treatment of Patients with Alzheimer’s Disease (AD) at the 2023 Alzheimer’s Association International Conference (AAIC)
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics, Inc. (Coya) Broadens its COYA 300 Biologics Patent Estate for the Exclusive Patent Rights and Know-how in treatment of Parkinson's Disease (PD)
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Strengthens its Management Team with the Appointment of Dr. Michelle Frazier as Senior Vice President of Regulatory Affairs
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics’ CEO Dr. Howard Berman’s Letter to Stockholders
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Reports Additional Biomarker and Imaging Data Showing Decrease in Neuroinflammation with COYA 301 in Alzheimer’s Disease
Via Get News
News headline image
Marsh & McLennan To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Thursday ↗
Raymond James cut the price target for Brinker International, Inc. (NYSE: EAT) from $46 to $42.5. Raymond James analyst Brian Vaccaro maintained an Outperform rating. Brinker shares fell 6.3% to close... 
Via Benzinga
News headline image
Blood Biomarker, Brain Imaging Data Shows Coya Therapeutics' Alzheimer's Candidate Lowers Neuroinflammation ↗
Coya Therapeutics Inc (NASDAQ: COYA) reported additional biomarker and brain imaging results from an open-label proof-of-concept study for COYA 301 for  
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Coya Therapeutics Reports Additional Blood Biomarker and Brain Imaging Data Showing Decrease in Neuroinflammation Following Treatment with COYA 301 in Alzheimer’s Disease (AD)
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Why Bluejay Diagnostics Shares Are Trading Lower By 12%; Here Are 20 Stocks Moving Premarket ↗
Gainers Visionary Education Technology Holdings Group Inc. (NASDAQ: VEDU) shares rose 85.8% to $0.7985 in pre-market trading. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >